Sign in

Why one type of chemotherapy works best in bladder cancer: Study reveals

The study shows that a certain type of chemotherapy, when paired with immunotherapy, can boost immune system's ability to fight bladder cancer.

Published on: Jan 28, 2024, 15:20:21 IST
ANI | Posted by , Washington DC
Share
Share via
  • facebook
  • twitter
  • linkedin
  • whatsapp
Copy link
  • copy link

According to a study published in Cell Reports Medicine in January, researchers at Tisch Cancer Institute showed that a certain form of chemotherapy boosts the immune system's ability to fight bladder cancer, especially when paired with immunotherapy.

Why one type of chemotherapy works best in bladder cancer: Study reveals (Twitter/MedscapeCME)
Why one type of chemotherapy works best in bladder cancer: Study reveals (Twitter/MedscapeCME)

These findings may explain why the approach, cisplatin chemotherapy, can lead to cure in a small subset of patients with metastatic, or advanced, bladder cancer. Researchers also believe that their findings could explain why clinical trials combining another type of chemotherapy, carboplatin-based chemo, with immunotherapy have not been successful but others that use cisplatin with immunotherapy are successful.

ALSO READ: Bladder cancer: Risk factors, tips to manage it

We're now on WhatsApp. Click to join

"We have known for decades that cisplatin works better than carboplatin in bladder cancer, however, the mechanisms underlying those clinical observations have remained elusive until now," said the study's lead author Matthew Galsky, M.D., Co-Director of the Center of Excellence for Bladder Cancer at The Tisch Cancer Institute at Mount Sinai. "This study provides clues as to why cisplatin-based chemotherapy may achieve durable disease control in a subset of patients with metastatic bladder cancer, provides clues as to which patients may derive such benefit, and provides a foundation for building even better treatment regimens that exploit the immunomodulatory effects of cisplatin-based chemotherapy."

Bladder cancer affects about 83,000 people in the United States annually. Metastatic bladder cancer is particularly hard to cure with current treatments, so these findings are an important step to most effectively use the drugs available and determine effective combination therapies.

The study found that cisplatin chemotherapy may work better when the body has generated a pre-existing, but restrained, immune response against the tumor. The study further found that cisplatin damages DNA in cancer cells, which may lead to changes in expression of genes that might improve the ability of the body's immune system to detect cancer cells.

Catch every big hit, every wicket with Crick-it, a one stop destination for Live Scores, Match Stats, Quizzes, Polls & much more. Explore now!.

Catch your daily dose of Fashion, Taylor Swift, Health, Festivals, Travel, Relationship, Recipe and all the other Latest Lifestyle News on Hindustan Times Website and APPs.
This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.